Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.
Eugenie YoungerSaskia LitièreAxel Le CesneOlivier MirHans GelderblomAntoine ItalianoSandrine MarreaudRobin Lewis JonesAlessandro GronchiWinette T A van der GraafPublished in: The oncologist (2018)
This analysis demonstrates that elderly patients with advanced soft tissue sarcoma are underrepresented in clinical trials of first-line chemotherapy by the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Furthermore, the elderly participants were generally of excellent performance status, which is not representative of an unselected elderly population. These data provide rationale for development of novel trials for elderly patients that are not only for "elite" patients but include comprehensive geriatric assessments for risk stratification. Because chemotherapy for advanced soft tissue sarcomas is largely given with palliative intent, incorporation of health-related quality of life measures with traditional endpoints will provide a more holistic approach to future clinical trials.
Keyphrases
- soft tissue
- clinical trial
- middle aged
- community dwelling
- end stage renal disease
- locally advanced
- newly diagnosed
- chronic kidney disease
- ejection fraction
- bone mineral density
- randomized controlled trial
- electronic health record
- adipose tissue
- palliative care
- papillary thyroid
- body composition
- phase ii
- prognostic factors
- metabolic syndrome
- study protocol
- current status
- machine learning
- young adults
- radiation therapy
- skeletal muscle
- squamous cell
- replacement therapy
- patient reported outcomes
- double blind